Metformin may reduce delirium-risk, mortality in patients with type 2 diabetes

The use of metformin in patients with type 2 diabetes may reduce delirium risk and mortality, according to a study.

In this retrospective cohort study, the 3-year mortality of 242 patients with type 2 diabetes mellitus not receiving metformin and 264 patients with type 2 diabetes receiving metformin.

Overall, 36% and 29.2% of patients not on metformin and on metformin, respectively, experienced delirium. When confounding factors were controlled for, prior use of metformin was found to reduce the risk of delirium in patients with diabetes.

The 3-year mortality was higher in patients without compared to patients with metformin. When confounding factors were controlled for, prior use of metformin was found to decrease the risk of 3-year mortality.

Reference
Yamanashi T, Anderson ZE, Modukuri M, et al. The potential benefit of metformin to reduce delirium risk and mortality: a retrospective cohort study. Aging (Albany NY). 2022;14. doi: 10.18632/aging.204393. Epub ahead of print. PMID: 36399107.